ReviewThe AAPS journal2006
New paradigms and tools in drug design for pain and addiction.
Review in The AAPS journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters.Bioorganic & medicinal chemistry · 2021Article
- Opioid Receptor Activity and Analgesic Potency of DPDPE Peptide Analogues Containing a Xylene Bridge.ACS medicinal chemistry letters · 2017Article
- Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.Journal of heterocyclic chemistry · 2017Article
- Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.The Yale journal of biology and medicine · 2017Review
- Cyclic non-opioid dynorphin A analogues for the bradykinin receptors.Bioorganic & medicinal chemistry letters · 2016Article
- Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.Bioorganic & medicinal chemistry letters · 2015Article
- Design, synthesis, and biological evaluation of a series of bifunctional ligands of opioids/SSRIs.Bioorganic & medicinal chemistry · 2015Article
- Structure-activity relationships of non-opioid [des-Arg(7)]-dynorphin A analogues for bradykinin receptors.Bioorganic & medicinal chemistry letters · 2014Article
- Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.Future medicinal chemistry · 2014Review
- Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.Annual review of pharmacology and toxicology · 2013Review
- Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.Bioorganic & medicinal chemistry · 2011Article
- Organic chemistry and biology: chemical biology through the eyes of collaboration.The Journal of organic chemistry · 2009Review
- Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain.Bioorganic & medicinal chemistry · 2009Article
- Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.Current opinion in pharmacology · 2007Review
- Blockade of non-opioid excitatory effects of spinal dynorphin A at bradykinin receptors.Receptors & clinical investigationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
New modalities providing safe and effective treatment of pain, especially prolonged pathological pain, have not appeared despite much effort. In this mini-review/overview we suggest that new paradigms of drug design are required to counter the underlying changes that occur in the nervous system that may elicit chronic pain states. We illustrate this approach with the example of designing, in a single ligand, molecules that have agonist activity at mu and delta opioid receptors and antagonist activities at cholecystokinin (CCK) receptors. Our findings thus far provide evidence in support of this new approach to drug design. We also report on a new biophysical method, plasmon waveguide resonance (PWR) spectroscopy, which can provide new insights into information transduction in G-protein coupled receptors (GPCRs) as illustrated by the delta opioid receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.